The article “Ethinyl Estradiol/Levonorgestrel (Seasonale) for Oral Contraception” (“STEPS,” April 15, 2005, page 1581) incorrectly referred to the intravaginal combination contraceptive device (NuvaRing) as an oral contraceptive and listed 12 rather than one to two for the number of pregnancies expected per 100 women each year who are using this product. In the first paragraph on page 1582, the second sentence should state, “According to the U.S. Food and Drug Administration, the number of pregnancies expected per 100 women each year are: less than one for intramuscular medroxyprogesterone (Depo-Provera); one for transdermal (Ortho Evra) and combined oral contraceptives; one to two for intravaginal combined contraceptives (NuvaRing); and two for progestin-only pills and ethinyl estradiol/levonorgestrel.” The online version of this article has been corrected.